Granted Patent
B2
US 8,624,019 · App. 12/847,237 · Granted Jan 7, 2014
ENA nucleic acid drugs modifying splicing in mRNA precursor
Assignees:
Masafumi Matsuo; Yasuhiro Takeshima; Daiichi Sankyo Company, Limited; Orphan Disease Treatment Institute Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
Claims (1)
1. An oligonucleotide consisting of the nucleotide sequence of SEQ ID NO: 78, or a pharmacologically acceptable salt thereof.
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 24, 2021
From: ORPHAN DISEASE TREATMENT INSTITUTE CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 057270/0430 →
INDIVIDUAL ADDRESS CHANGE
Recorded Jan 8, 2016
From: MATSUO, MASAFUMI; TAKESHIMA, YASUHIRO
To: MATSUO, MASAFUMI; TAKESHIMA, YASUHIRO
Reel/Frame 037459/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 30, 2013
From: NONPROFIT ORGANIZATION TRANSLATIONAL RESEARCH ORGANIZATION OF DUCHENNE MUSCULAR DYSTROPHY
To: ORPHAN DISEASE TREATMENT INSTITUTE CO., LTD.
Reel/Frame 030318/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 30, 2013
From: NONPROFIT ORGANIZATION TRANSLATIONAL RESEARCH ORGANIZATION OF DUCHENNE MUSCULAR DYSTROPHY
To: ORPHAN DISEASE TREATMENT INSTITUTE CO., LTD.
Reel/Frame 030319/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2012
From: KNC LABORATORIES CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 028819/0922 →
Priority Claims (2)
JP 2002-340857
· Nov 25, 2002
· national
JP 2003-204381
· Jul 31, 2003
· national
Continuity (2)
Division
10536258